A Single-Subject Method to Detect Pathways Enriched With Alternatively Spliced Genes
AffiliationUniv Arizona, Ctr Biomed Informat & Biostat
Univ Arizona, Dept Med
Univ Arizona, Grad Interdisciplinary Program Stat
Univ Arizona, BIO5 Inst
Univ Arizona, Canc Ctr
Univ Arizona, Hlth Sci
local false discovery rate
MetadataShow full item record
PublisherFRONTIERS MEDIA SA
CitationSchissler AG, Aberasturi D, Kenost C and Lussier YA (2019) A Single-Subject Method to Detect Pathways Enriched With Alternatively Spliced Genes. Front. Genet. 10:414. doi: 10.3389/fgene.2019.00414
JournalFRONTIERS IN GENETICS
Rights© 2019 Schissler, Aberasturi, Kenost and Lussier. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractRNA-Sequencing data offers an opportunity to enable precision medicine, but most methods rely on gene expression alone. To date, no methodology exists to identify and interpret alternative splicing patterns within pathways for an individual patient. This study develops methodology and conducts computational experiments to test the hypothesis that pathway aggregation of subject-specific alternatively spliced genes (ASGs) can inform upon disease mechanisms and predict survival. We propose the N-of-1 -pathways Alternatively Spliced (N1PAS) method that takes an individual patient's paired-sample RNA-Seq isoform expression data (e.g., tumor vs. non-tumor, before-treatment vs. during-therapy) and pathway annotations as inputs. N1PAS quantifies the degree of alternative splicing via Hellinger distances followed by two-stage clustering to determine pathway enrichment. We provide a clinically relevant "odds ratio" along with statistical significance to quantify pathway enrichment. We validate our method in clinical samples and find that our method selects relevant pathways (p < 0.05 in 4/6 data sets). Extensive Monte Carlo studies show N1PAS powerfully detects pathway enrichment of ASGs while adequately controlling false discovery rates. Importantly, our studies also unveil highly heterogeneous single-subject alternative splicing patterns that cohort-based approaches overlook. Finally, we apply our patient-specific results to predict cancer survival (FDR < 20%) while providing diagnostics in pursuit of translating transcriptome data into clinically actionable information. Software available at https://github.com/grizant/n1pas/tree/master.
NoteOpen access journal
VersionFinal published version
SponsorsUniversity of Arizona Health Sciences Center for Biomedical Informatics; BIO5 Institute, NIH [U01AI122275, HL132532, CA023074, 1UG3OD023171, 1S10RR029030]